Abstract 96P
Background
PD-1 blockade alone in heavily treated MSS/pMMR mCRC patients (pts) is ineffective. PD-1 blockade combined with antiangiogenic therapy has synergistic effects and has shown clinical benefits in several trials. TRAP aims to explore the efficacy and safety of TKIs combined with PD-1 blockade in TKI-responsive MSS/pMMR mCRC pts refractory to standard chemotherapy with or without anti-VEGF and/or anti-EGFR therapies. Here we report the updated results at the data cutoff of Feb 6, 2023.
Methods
Eligible pts were given 1 cycle of TKIs (fruquintinib 5mg or regorafenib 120mg, d1-21, q4w) and grouped by tumor response according to RECIST v1.1: arm A: reduction of target lesion to CR, PR or shrunken SD, or cavitation in metastatic lung lesions, or decrease in the density of liver metastatic target lesions ≥15%; arm B: enlarged SD; arm C: PD. Then arm B pts were given another cycle of TKIs and grouped again. Pts in arm A then received TKIs plus anti-PD-1 antibody (toripalimab 240mg, or sintilimab 200mg, i.v.gtt, q3w, until PD or up to 2 years), pts in arm B continued with TKIs until PD. The Simon 2-stage design tested the null 9-months (m) PFS rate of 27.1% vs. 55% (power = 0.90; α = 0.05). A total of >10 pts reaching ≥ 9-m PFS in 25 pts receiving TKI plus anti-PD-1 antibody is required to reject null hypothesis.
Results
49 pts were enrolled. Median age, 59 (34-72); male, 51.0%; ECOG PS 1, 100%; median prior regimens, 2 (1-4). 20 entered arm A in 46 evaluable pts. All pts in arm A had prior 5-FU and oxaliplatin, 85.0% had prior anti-VEGF and/or anti-EGFR therapies. In arm A, ORR was 15.0%, median follow-up was 21.6m, mPFS was 13.2m (95% CI, 8.95m-NA), 6-m, 9-m and 12-m PFS rates were 88.8% (95%CI, 75.3%-100%), 66.6% (95%CI, 46.2%-96.0%) and 50.8% (95%CI, 29.9%-86.0%). OS was not mature. The most common treatment-related adverse events (TRAEs) (total; Grade ≥3) were hand-foot skin reaction (43.8%; 18.8%), hypothyroidism (37.5%; 6.3%), hypertension (31.2%; 25.0%) and proteinuria (31.2%; 6.3%). No treatment related death was observed.
Conclusions
TKIs combined with PD-1 blockade has shown encouraging efficacy with acceptable toxicities in MSS/pMMR mCRC pts responsive to TKI treatment.
Clinical trial identification
NCT04483219.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract
101P - The coexistence of TP53 gain-of-function mutation and hypermethylation as a poor prognostic factor in BRAF wild-type metastatic colorectal cancer
Presenter: Kota Ouchi
Session: Poster Display
Resources:
Abstract